Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer-Reference-Cited by-同舟云学术

Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer

Published:2010-02-02 Issue:S4 Volume:116 Page:1075-1083
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Tagawa Scott T.,Beltran Himisha,Vallabhajosula Shankar,Goldsmith Stanley J.,Osborne Joseph,Matulich Dan,Petrillo Kristen,Parmar Sarojben,Nanus David M.,Bander Neil H.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24795/fullpdf

Reference71 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin [serial online].,2008

2. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer;Albertsen;JAMA.,1998

3. 20-year outcomes following conservative management of clinically localized prostate cancer;Albertsen;JAMA.,2005

4. Scher HI Leibel SA Fuks Z Cordon-Cardo C Scardino PT Cancers of the prostate DeVita VT Jr Hellman S Rosenberg SA 7th ed. Philadelphia, PA Lippincott Williams & Wilkins 2005

5. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A canadian randomized trial with palliative end points;Tannock;J Clin Oncol.,1996

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in Dedicated Prostate PET Instrumentation;PET Clinics;2024-01

2. Procalcitonin assessment by using optical sensor terbium hydrochlorothiazide complex for early diagnosis of lung cancer;Microchemical Journal;2023-10

3. Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma;Pharmaceuticals;2023-07-12

4. The “Ins and Outs” of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy;Advances in Experimental Medicine and Biology;2023

5. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer;Drug Resistance Updates;2022-09